Margrethe Sørgaard appointed senior vice president of clinical operations and pharmacovigilance at Calluna Pharma

Calluna Pharma has announced that it has appointed Margrethe Sørgaard as senior vice president of clinical operations and pharmacovigilance.
Margrethe will join the company’s R&D team and will oversee the strategic development of its clinical programmes in line with the relevant regulatory guidelines and safety requirements.
Margrethe brings with her over 25 years of experience from her past leading positions within clinical development and operation, medical affairs and drug safety/ pharmacovigilance. Previously, Margrethe worked as senior director of safety and PV at BioInvent International AB, prior to this working as vice president and head of clinical development at Circio Holdings ASA. She also has experience within regulatory pre- and post-marketing processes and quality assurance, having worked as an EU qualified person for phamacovigilance at Photocure ASA and head of unit for safety assessment and GCP/PhV inspector at the Norwegian Medicines Agency (NOMA).
John Montana PhD, chief executive officer at Calluna Pharma, stated: “We are excited to have Margrethe join us at a time when we are preparing several of our innovative programmes for clinical trials. We look forward to leveraging Margrethe’s expertise in all aspects of clinical development and clinical operations, to help ensure Calluna’s clinical programmes run according to the company’s strategy, applicable legislation, regulations and guidelines, while prioritising patient safety.”
Commenting on her new role, Margrethe added: “I am thrilled to join Calluna’s team at such an exciting stage of the company’s development. Calluna’s groundbreaking approach in targeting upstream innate immune amplifiers has the potential to revolutionise treatment across a spectrum of diseases associated with chronic inflammation and fibrosis, improving patient outcomes and fulfilling unmet medical needs. I look forward to becoming an integral part of the development of our clinical programmes.”